OTC$AIM
AIM ImmunoTech Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
AIM ImmunoTech reported a decrease in net loss for the fiscal year 2024, primarily driven by reduced general and administrative expenses and research and development costs.
AIM ImmunoTech Inc. reported a significant decrease in net loss for the fiscal year ended December 31, 2024, primarily due to reduced general and administrative expenses and research and development costs. The company's total revenues remained relatively stable, primarily from clinical treatment programs. Despite the improved net loss, the company continues to face challenges with a working capital deficit and its stockholders' equity being below NYSE American listing requirements, raising substantial doubt about its ability to continue as a going concern.
- Net loss decreased by 40% to $17,320,000 in 2024 from $28,962,000 in 2023.
- General and administrative expenses decreased by $7,423,000, largely due to lower legal, financial, and consulting fees.
- Research and development expenses decreased by $4,742,000, driven by reductions in company-sponsored clinical trial expenses and outside consultant costs.
- The company's stockholders' equity was below the minimum NYSE American listing requirements, raising substantial doubt about its ability to continue as a going concern.
Headline financials
Revenue & EPS history
AIM ImmunoTech · Revenue · Quarterly
$170K
Forward guidance
The company's forward guidance indicates a continued focus on clinical trials for Ampligen, particularly for pancreatic cancer and Post-COVID conditions, with efforts to secure additional funding and maintain NYSE American listing compliance. The company aims to advance its therapeutic products while managing financial constraints.
Tailwinds
- Continued focus on clinical trials for Ampligen in pancreatic cancer and Post-COVID conditions, with promising preliminary data.
- Engagement of Amarex Clinical Research to manage follow-up IND application for avian influenza combination therapy.
- Erasmus Medical Center Safety Committee approval for Phase 2 Study of Ampligen and Imfinzi for pancreatic cancer.
- Ongoing efforts to secure collaborative grants from government and industry to defray study costs.
- Strategic focus on finding senior co-development partners with capital and expertise to commercialize therapeutic aspects.
Headwinds
- Substantial doubt about the company's ability to continue as a going concern due to recurring losses and net capital deficiency.
- Current stockholders' equity is below NYSE American minimum listing requirements, risking delisting.
- Need for additional funding to meet anticipated operational cash needs and fund current/future clinical trials.
- Uncertainty regarding the timing and outcome of FDA approvals for drug products.
- Potential for significant dilution if additional equity financing is secured.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2024
+20.2%
Avg return
Earnings day
-3.9%
Avg return
5 days after
-10.1%
Avg return
30 days after
50%
30 / 60 earnings
Positive
+946.2%
Q3 2011
Best reaction
-18.8%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.8% | — | — | |
| Q4 2025 | -18.8% | -30.6% | -38.8% | |
| Q3 2025 | -7.6% | -4.9% | -5.6% | |
| Q2 2025 | +3.1% | -3.5% | +1.2% | |
| Q1 2025 | +0.0% | +0.0% | -25.6% | |
| Q4 2024 | +2.2% | -25.0% | -33.3% | |
| Q3 2024 | -8.8% | -20.0% | -12.0% | |
| Q2 2024 | +7.4% | +14.8% | +11.1% | |
| Q1 2024 | +0.9% | +2.5% | +12.5% | |
| Q4 2023 | -2.8% | +0.0% | -18.4% | |
| Q3 2023 | +7.3% | +2.3% | +20.5% | |
| Q2 2023 | -9.3% | -10.1% | -7.2% | |
| Q1 2023 | -3.5% | +6.8% | +4.5% | |
| Q4 2022 | +3.6% | +0.0% | +11.6% | |
| Q3 2022 | +1.0% | +0.0% | -27.1% | |
| Q2 2022 | -3.8% | -7.8% | -16.9% | |
| Q1 2022 | +2.4% | -7.3% | -8.3% | |
| Q4 2021 | -1.9% | +1.9% | -2.8% | |
| Q3 2021 | -7.0% | -14.6% | -35.1% | |
| Q2 2021 | -2.5% | -3.0% | -2.5% | |
| Q1 2021 | +3.0% | +6.0% | +8.6% | |
| Q4 2020 | +11.7% | +8.9% | -99.0% | |
| Q3 2020 | +6.3% | +3.7% | -3.7% | |
| Q2 2020 | +0.4% | -5.9% | -22.7% | |
| Q1 2020 | +8.9% | +4.7% | +10.2% | |
| Q4 2019 | +9.8% | +2.6% | -21.8% | |
| Q3 2019 | -5.6% | -8.2% | -8.2% | |
| Q2 2019 | +2.2% | +3.8% | +1.1% | |
| Q1 2019 | -6.7% | -13.3% | -23.0% | |
| Q4 2018 | +0.0% | -6.2% | +31.3% | |
| Q3 2018 | +0.0% | -9.1% | -13.6% | |
| Q2 2018 | -6.7% | -13.3% | -23.3% | |
| Q1 2018 | +0.0% | +3.3% | +0.0% | |
| Q4 2017 | +12.5% | +2.5% | -20.0% | |
| Q3 2017 | +0.0% | +0.0% | -3.1% | |
| Q2 2017 | +0.0% | -2.4% | -22.0% | |
| Q1 2017 | -6.3% | -17.2% | -18.8% | |
| Q4 2016 | +5.7% | +0.0% | +26.4% | |
| Q3 2016 | -2.2% | -9.9% | -11.0% | |
| Q1 2016 | +9.1% | — | — | |
| Q4 2015 | +8.3% | — | — | |
| Q3 2015 | +7.1% | — | — | |
| Q2 2015 | +0.0% | — | — | |
| Q1 2015 | -7.4% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | -4.9% | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | -7.7% | — | — | |
| Q1 2013 | +0.3% | — | — | |
| Q4 2012 | +1.9% | — | — | |
| Q3 2012 | +281.0% | — | — | |
| Q2 2012 | +0.5% | — | — | |
| Q1 2012 | -1.9% | — | — | |
| Q4 2011 | +1.9% | — | — | |
| Q3 2011 | +946.2% | — | — | |
| Q2 2011 | -13.4% | — | — | |
| Q1 2011 | +2.4% | — | — | |
| Q4 2010 | -6.3% | — | — | |
| Q3 2010 | +1.3% | — | — | |
| Q2 2010 | +0.6% | — | — | |
| Q1 2010 | +3.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro